Glycomacropeptide formula with docosahexaenoic acid with low phenylalanine
Brand: PKU GMPro®
PBAC's latest decision on Glycomacropeptide formula with docosahexaenoic acid with low phenylalanine: Recommended (2018). Considered for Treatment of phenylketonuria (PKU) in patients aged 3 years or older.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Patients aged 3 years or older with phenylketonuria (PKU).
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
PKU Glytactin RTD 10
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Listed on equivalent cost per gram of protein equivalent (PE) as the comparator.